@article{10.11648/j.bmb.20240901.14,
  author = {Babacar Faye and Bineta Ndiaye and Cheikh Madické Ndiaye and Mame Diarra Bousso Lam and Ismaïl Barkiré and Micailou Magassouba and Cathy Cissé and Aissatou Ngom and Alioune Dièye},
  title = {Highly Active Antiretroviral Treatment of HIV-1 Patients, Molecular Evaluation of AZT+3TC+EFV Regim},
  journal = {Biochemistry and Molecular Biology},
  volume = {9},
  number = {1},
  pages = {23-29},
  doi = {10.11648/j.bmb.20240901.14},
  url = {https://doi.org/10.11648/j.bmb.20240901.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bmb.20240901.14},
  abstract = {Background: Antiretroviral therapy (ART) is an effective way to reduce the risk of HIV transmission. Several studies have demonstrated a reduction of sexual transmission of HIV in people on ART treatment and the main objective of antiretroviral treatment is to avoid the increase of, morbidity and mortality associated to AIDS. Furthermore, the 2030 UNAIDS target requires the achievement of the 3 “95s”, with the 2nd and 3rd linked to the establishment and success of treatment. This is why the evaluation of therapeutic regimens is necessary to achieve these targets. The aim of our study was therefore to assess the effectiveness of the AZT+3TC+EFV regimen in the antiretroviral therapy of HIV-1 infection. Material and methods: This is a retrospective study on the treatment of HIV-1 positive patients. For this study, 372 HIV positive patients were included and followed at the molecular biology laboratory of the HIV/AIDS program at Ouakam Military Hospital in Dakar, Senegal from 2014 to 2021. All plasma samples came from HIV-1 positive patients. Plasma viral load were performed on Abbott Real-Time HIV-1® (m2000sp/rt) and COBAS®AmpliPrep TaqMan® (Roche) v.2.0. p-valueResults: 372 patients met the selection criteria, 62.1% were women and the sex ratio M/F was 0.61. The largest age group [40-60] represented 40.1% and those aged 60 was the smallest group with 5.4%. At 6 months, 12 months and 24 months of treatment, viral suppression was 41.1%, 65.9% and 80.6%, respectively. At 24 months of treatment, virological suppression was linked to age. Virological success at 24 months was 95%, 78.5%, 86.3%, 72.2% respectively for patients aged 65 or over, [45-65]years, [25-45] years and [0-25] years, (P= 0.02). At 12 months, the undetectable viral load was significantly higher in women with 70.1% than in men with 58.2% (P=0.02). The rate of therapeutic failure after 24 months of treatment was higher in men (22.7%) than in women (17.3%) (P=0.2). Therapeutic failure was significantly higher among the youngest aged [0-25] years with 27.8%. It was 13.7%, 21.5% and 5% for the groups [25-45] years, [45-65] years and 65 years or more respectively (P=0.02). Conclusion: AZT+3TC+EFV treatment gives HIV-1 patients a high virological suppression rate at 24 months. Sex was associated with viral suppression at 12 months being significantly higher in women. It was significantly greater in the elderly at 24 months of treatment. Therapeutic failure was linked to age after 24 months of treatment and higher in young people. This treatment remains effective and inexpensive, hence its interest for countries with limited resources.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Highly Active Antiretroviral Treatment of HIV-1 Patients, Molecular Evaluation of AZT+3TC+EFV Regim
AU  - Babacar Faye
AU  - Bineta Ndiaye
AU  - Cheikh Madické Ndiaye
AU  - Mame Diarra Bousso Lam
AU  - Ismaïl Barkiré
AU  - Micailou Magassouba
AU  - Cathy Cissé
AU  - Aissatou Ngom
AU  - Alioune Dièye
Y1  - 2024/01/18
PY  - 2024
N1  - https://doi.org/10.11648/j.bmb.20240901.14
DO  - 10.11648/j.bmb.20240901.14
T2  - Biochemistry and Molecular Biology
JF  - Biochemistry and Molecular Biology
JO  - Biochemistry and Molecular Biology
SP  - 23
EP  - 29
PB  - Science Publishing Group
SN  - 2575-5048
UR  - https://doi.org/10.11648/j.bmb.20240901.14
AB  - Background: Antiretroviral therapy (ART) is an effective way to reduce the risk of HIV transmission. Several studies have demonstrated a reduction of sexual transmission of HIV in people on ART treatment and the main objective of antiretroviral treatment is to avoid the increase of, morbidity and mortality associated to AIDS. Furthermore, the 2030 UNAIDS target requires the achievement of the 3 “95s”, with the 2nd and 3rd linked to the establishment and success of treatment. This is why the evaluation of therapeutic regimens is necessary to achieve these targets. The aim of our study was therefore to assess the effectiveness of the AZT+3TC+EFV regimen in the antiretroviral therapy of HIV-1 infection. Material and methods: This is a retrospective study on the treatment of HIV-1 positive patients. For this study, 372 HIV positive patients were included and followed at the molecular biology laboratory of the HIV/AIDS program at Ouakam Military Hospital in Dakar, Senegal from 2014 to 2021. All plasma samples came from HIV-1 positive patients. Plasma viral load were performed on Abbott Real-Time HIV-1® (m2000sp/rt) and COBAS®AmpliPrep TaqMan® (Roche) v.2.0. p-valueResults: 372 patients met the selection criteria, 62.1% were women and the sex ratio M/F was 0.61. The largest age group [40-60] represented 40.1% and those aged 60 was the smallest group with 5.4%. At 6 months, 12 months and 24 months of treatment, viral suppression was 41.1%, 65.9% and 80.6%, respectively. At 24 months of treatment, virological suppression was linked to age. Virological success at 24 months was 95%, 78.5%, 86.3%, 72.2% respectively for patients aged 65 or over, [45-65]years, [25-45] years and [0-25] years, (P= 0.02). At 12 months, the undetectable viral load was significantly higher in women with 70.1% than in men with 58.2% (P=0.02). The rate of therapeutic failure after 24 months of treatment was higher in men (22.7%) than in women (17.3%) (P=0.2). Therapeutic failure was significantly higher among the youngest aged [0-25] years with 27.8%. It was 13.7%, 21.5% and 5% for the groups [25-45] years, [45-65] years and 65 years or more respectively (P=0.02). Conclusion: AZT+3TC+EFV treatment gives HIV-1 patients a high virological suppression rate at 24 months. Sex was associated with viral suppression at 12 months being significantly higher in women. It was significantly greater in the elderly at 24 months of treatment. Therapeutic failure was linked to age after 24 months of treatment and higher in young people. This treatment remains effective and inexpensive, hence its interest for countries with limited resources.

VL  - 9
IS  - 1
ER  - 

Copy | Download